Sanofi, Formation Bio, and OpenAI Launch AI Tool 'Muse' to Accelerate Clinical Trial Recruitment
核心洞察
Sanofi, Formation Bio (搜索), and OpenAI (搜索) have collaborated to launch Muse, an AI-powered tool designed to optimize patient recruitment for clinical trials.
Muse analyzes scientific literature, real-world evidence, and patient population insights to expedite recruitment strategy and content creation.
Sanofi plans to implement Muse in Phase 3 studies for multiple sclerosis (搜索) (MS), leveraging its data and expertise in treating the condition.
Formation Bio (搜索), in collaboration with OpenAI (搜索) and Sanofi, has introduced Muse, an AI-driven tool aimed at accelerating and improving drug development by optimizing patient recruitment for clinical trials. This marks the first outcome of the partnership between the three entities, combining their pharmaceutical expertise and AI capabilities to expedite the delivery of breakthrough therapies to patients.
Muse is designed to shorten patient recruitment timelines by accelerating the creation of recruitment strategies and content from months to minutes. The AI tool analyzes extensive scientific literature, real-world evidence, and insights on diseases and patient populations. This comprehensive analysis delivers strategic opportunities and faster preparation of patient recruitment strategies, potentially accomplishing with a single AI tool what typically requires large teams and manual review.
Sanofi intends to implement Muse in upcoming Phase 3 clinical trials for multiple sclerosis (搜索) (MS). Sanofi will contribute data and expertise on MS, drawing from its experience in delivering innovative treatments to patients affected by this condition. Muse develops tailored strategies and materials designed for diverse patient populations, including historically underrepresented groups, to enhance inclusiveness and representation in clinical trials. This approach aims to expand participation and capture broader trial data, contributing to more reliable and generalizable insights.
Muse also incorporates an LLM agent that integrates Institutional Review Board (IRB) and regulatory guidelines. This feature aims to automatically generate high-quality materials that adhere to compliance best practices. When combined with human experts, this reduces the risk of regulatory setbacks, promoting faster and more efficient trial progression. AI safety and data privacy are embedded throughout Muse's development and deployment, reflecting the commitment of all three companies to the responsible use of AI. Muse relies on research publications and other public and proprietary data sources, none of which contain personally identifiable information (PII).
According to the collaboration, Muse is designed for use across a wide range of therapeutic areas. "At scale, this AI-driven development approach can accelerate the delivery of new medicines and reshape healthcare worldwide. Muse is just the start--one of the many AI innovations we're building for drug development."